ich denke auch, daß er das Datum bewusst gewählt hat. Zumal alle relevanten Timelines als erste Ziele Ende Q1/2014 haben. Und das ist ja dann bald. Mit 'ner News heute oder morgen läge er voll im Plan und würde natürlich die Kurse beider Aktien kräftig pushen.
~~CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS
Abstract
Disclosed are therapeutic methods for ex-vivo activation of immune cells from a cancer patient for the purpose of inducing tumor regression and/or suppressing metastasis and/or tumor recurrence. In one embodiment mononuclear cells of a patient are isolated from peripheral blood and activated by a combination of innate immune system activators together with means allowing for T cell activation.
Bio-Matrix Scientific Group, Inc., (OTCBB: BMSN) a development stage company, through its subsidiary, Regen BioPharma, Inc., intends to engage primarily in the development of regenerative medical applications. It develops HemaXellerate, a cellular drug to heal damaged bone marrow; and HemaXellerate I, which is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.
Regen BioPharma, Inc., a wholly-owned publicly traded subsidiary of Bio-Matrix Scientific Group, Inc., is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through preclinical and Phase I/II clinical trials. www.regenbiopharma.com
Thread abonnieren
